Pharmacoepidemiology Study to Define the Long-term Safety Profile of Tenofovir Disoproxil Fumarate (Tenofovir DF, Viread) and Describe the Management of Tenofovir DF-associated Renal and Bone Toxicity in Chronic Hepatitis B (CHB)-Infected Adolescents Aged 12 to <18 Years in Europe
Phase of Trial: Phase IV
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 19 Apr 2018 Status changed from active, no longer recruiting to completed.
- 06 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
- 08 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Mar 2018.